A detailed history of Susquehanna International Group, LLP transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 64,221 shares of AUPH stock, worth $521,474. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,221
Previous 363,767 82.35%
Holding current value
$521,474
Previous $2.08 Million 77.37%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.32 - $7.33 $1.59 Million - $2.2 Million
-299,546 Reduced 82.35%
64,221 $470,000
Q2 2024

Aug 15, 2024

BUY
$4.81 - $5.78 $125,108 - $150,337
26,010 Added 7.7%
363,767 $2.08 Million
Q1 2024

May 07, 2024

SELL
$4.93 - $9.31 $3.43 Million - $6.47 Million
-694,847 Reduced 67.29%
337,757 $1.69 Million
Q4 2023

Feb 14, 2024

BUY
$7.13 - $9.49 $3.03 Million - $4.03 Million
424,708 Added 69.87%
1,032,604 $9.28 Million
Q3 2023

Nov 14, 2023

SELL
$7.77 - $12.27 $1.53 Million - $2.41 Million
-196,590 Reduced 24.44%
607,896 $4.72 Million
Q2 2023

Aug 11, 2023

SELL
$8.96 - $11.69 $2.27 Million - $2.96 Million
-253,151 Reduced 23.94%
804,486 $7.79 Million
Q1 2023

May 16, 2023

BUY
$5.94 - $11.27 $2.23 Million - $4.24 Million
375,975 Added 55.16%
1,057,637 $11.6 Million
Q4 2022

Feb 14, 2023

SELL
$4.11 - $8.14 $389,295 - $771,012
-94,719 Reduced 12.2%
681,662 $2.94 Million
Q3 2022

Nov 14, 2022

SELL
$6.66 - $12.39 $6.26 Million - $11.7 Million
-940,586 Reduced 54.78%
776,381 $5.84 Million
Q2 2022

Aug 15, 2022

SELL
$8.95 - $12.8 $1.84 Million - $2.64 Million
-206,038 Reduced 10.71%
1,716,967 $17.3 Million
Q1 2022

May 16, 2022

SELL
$10.05 - $22.48 $14.8 Million - $33 Million
-1,469,001 Reduced 43.31%
1,923,005 $23.8 Million
Q4 2021

Feb 14, 2022

SELL
$17.78 - $33.08 $7.66 Million - $14.3 Million
-430,821 Reduced 11.27%
3,392,006 $77.6 Million
Q3 2021

Nov 15, 2021

BUY
$10.93 - $23.55 $15.4 Million - $33.1 Million
1,406,345 Added 58.2%
3,822,827 $84.6 Million
Q2 2021

Aug 11, 2021

BUY
$10.0 - $14.52 $10.6 Million - $15.4 Million
1,062,348 Added 78.45%
2,416,482 $31.3 Million
Q1 2021

May 17, 2021

SELL
$12.3 - $18.73 $9.01 Million - $13.7 Million
-732,263 Reduced 35.1%
1,354,134 $17.6 Million
Q4 2020

Feb 16, 2021

BUY
$12.94 - $16.05 $8.71 Million - $10.8 Million
673,219 Added 47.64%
2,086,397 $28.9 Million
Q3 2020

Nov 16, 2020

BUY
$13.19 - $16.66 $4.19 Million - $5.29 Million
317,579 Added 28.99%
1,413,178 $20.8 Million
Q2 2020

Aug 14, 2020

SELL
$14.12 - $18.33 $40,270 - $52,277
-2,852 Reduced 0.26%
1,095,599 $17.8 Million
Q1 2020

May 15, 2020

BUY
$11.34 - $21.46 $2.68 Million - $5.08 Million
236,581 Added 27.45%
1,098,451 $15.9 Million
Q4 2019

Feb 14, 2020

BUY
$3.88 - $21.42 $851,015 - $4.7 Million
219,334 Added 34.14%
861,870 $17.5 Million
Q3 2019

Nov 14, 2019

BUY
$5.34 - $6.59 $802,233 - $990,022
150,231 Added 30.52%
642,536 $3.43 Million
Q2 2019

Aug 16, 2019

BUY
$6.05 - $6.75 $11,277 - $12,582
1,864 Added 0.38%
492,305 $3.24 Million
Q2 2019

Aug 14, 2019

SELL
$6.05 - $6.75 $476,262 - $531,366
-78,721 Reduced 13.83%
490,441 $3.23 Million
Q1 2019

May 15, 2019

BUY
$6.06 - $7.64 $1.8 Million - $2.27 Million
297,328 Added 109.38%
569,162 $3.7 Million
Q4 2018

Feb 14, 2019

BUY
$5.08 - $6.83 $721,639 - $970,235
142,055 Added 109.46%
271,834 $1.85 Million
Q3 2018

Nov 14, 2018

SELL
$5.27 - $6.64 $425,510 - $536,126
-80,742 Reduced 38.35%
129,779 $862,000
Q2 2018

Aug 14, 2018

BUY
$5.06 - $6.36 $584,394 - $734,535
115,493 Added 121.54%
210,521 $1.19 Million
Q1 2018

May 15, 2018

SELL
$4.85 - $5.99 $219,860 - $271,538
-45,332 Reduced 32.3%
95,028 $493,000
Q4 2017

Feb 14, 2018

SELL
$4.53 - $7.09 $757,941 - $1.19 Million
-167,316 Reduced 54.38%
140,360 $636,000
Q3 2017

Nov 14, 2017

BUY
$5.71 - $6.9 $1.76 Million - $2.12 Million
307,676
307,676 $1.93 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.